Plasma ESR1 mutations and outcome to first-line paclitaxel and bevacizumab in patients with advanced ER-positive/HER2-negative breast cancer

ConclusionsPresence ofESR1 mutations in baseline ctDNA might not be associated with inferior PFS and OS in advanced breast cancer patients treated with paclitaxel/bevacizumab.

Source: Breast Cancer Research and Treatment - June 6, 2023 Category: Cancer & Oncology Source Type: research